Miller Howard Investments Inc. NY Buys 955,891 Shares of GSK PLC Sponsored ADR (NYSE:GSK)

Miller Howard Investments Inc. NY raised its holdings in GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 138.4% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,646,791 shares of the pharmaceutical company's stock after purchasing an additional 955,891 shares during the period. GSK makes up about 2.0% of Miller Howard Investments Inc. NY's portfolio, making the stock its 14th largest holding. Miller Howard Investments Inc. NY owned approximately 0.08% of GSK worth $63,797,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Parkside Financial Bank & Trust raised its stake in GSK by 470.1% in the fourth quarter. Parkside Financial Bank & Trust now owns 992 shares of the pharmaceutical company's stock valued at $34,000 after purchasing an additional 818 shares in the last quarter. Lee Danner & Bass Inc. acquired a new stake in shares of GSK during the 4th quarter worth approximately $39,000. Bank Julius Baer & Co. Ltd Zurich bought a new position in GSK in the fourth quarter valued at approximately $40,000. Atala Financial Inc acquired a new position in GSK during the fourth quarter valued at approximately $45,000. Finally, First Pacific Financial bought a new stake in GSK during the first quarter worth $45,000. Institutional investors own 15.74% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. Hsbc Global Res upgraded GSK to a "strong sell" rating in a research note on Monday, April 28th. Wall Street Zen cut GSK from a "buy" rating to a "hold" rating in a research report on Friday, May 30th. Berenberg Bank reissued a "hold" rating on shares of GSK in a research note on Tuesday, June 3rd. Finally, BNP Paribas assumed coverage on shares of GSK in a research note on Tuesday, April 15th. They issued a "neutral" rating and a $35.25 price target on the stock. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $37.38.

GSK Trading Down 0.8%

GSK stock traded down $0.31 during trading hours on Thursday, hitting $38.21. The stock had a trading volume of 2,655,343 shares, compared to its average volume of 5,214,926. The stock has a market cap of $78.22 billion, a price-to-earnings ratio of 19.69, a P/E/G ratio of 1.36 and a beta of 0.50. The company has a quick ratio of 0.58, a current ratio of 0.87 and a debt-to-equity ratio of 1.21. The business's 50 day simple moving average is $38.97 and its 200-day simple moving average is $37.03. GSK PLC Sponsored ADR has a one year low of $31.72 and a one year high of $44.67.

GSK (NYSE:GSK - Get Free Report) last issued its quarterly earnings data on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.08 by $0.05. GSK had a net margin of 9.89% and a return on equity of 48.82%. The business had revenue of $10.06 billion during the quarter, compared to analyst estimates of $7.52 billion. During the same quarter last year, the business earned $0.43 EPS. The firm's quarterly revenue was up 2.1% on a year-over-year basis. On average, equities analysts predict that GSK PLC Sponsored ADR will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, July 10th. Investors of record on Friday, May 16th will be paid a $0.4216 dividend. This is a boost from GSK's previous quarterly dividend of $0.39. The ex-dividend date is Friday, May 16th. This represents a $1.69 annualized dividend and a dividend yield of 4.41%. GSK's payout ratio is currently 87.11%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.